Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom

Conclusion Newer DMTs were associated with a lower risk of clinical and radiologic relapses in patients compared with injectables. Our study adds weight to the argument for an imminent shift in practice toward the use of newer, more efficacious DMTs in the first instance. Classification of Evidence This study provides Class IV evidence that newer DMTs (oral or infusions) are superior to injectables (interferon beta/glatiramer acetate) in reducing both clinical relapses and radiologic activity in children with RRMS.

http://nn.neurology.org/cgi/content/short/8/4/e1008?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - May 21, 2021 Category: Neurology Authors: Abdel-mannan, O. A., Manchoon, C., Rossor, T., Southin, J.-C., Tur, C., Brownlee, W., Byrne, S., Chitre, M., Coles, A., Forsyth, R., Kneen, R., Mankad, K., Ram, D., West, S., Wright, S., Wassmer, E., Lim, M., Ciccarelli, O., Hemingway, C., Hacohen, Y., on Tags: MRI, All Pediatric, Class IV, Multiple sclerosis Article Source Type: research